Telehealth Intake Rules for Ketamine Programs in 2026

telehealthketamine clinicDEAprescribing rulesintake2026

Telehealth-based ketamine programs expanded rapidly between 2020 and 2024, driven partly by the DEA’s COVID-era flexibilities that allowed practitioners to prescribe controlled substances via telemedicine without a prior in-person visit. Those flexibilities — and the regulatory turbulence around their expiration — directly affect how ketamine clinics can conduct remote intake and evaluation. If you operate or are building a ketamine program with a telehealth component, understanding the current rules is not optional.

What Changed When the COVID Flexibilities Expired

When the federal COVID public health emergency ended in May 2023, the DEA faced pressure to address the future of telemedicine prescribing for controlled substances. The agency proposed rules in 2023 that would have significantly restricted telehealth prescribing of Schedule III-V substances, including ketamine. After significant comment periods and public debate, the DEA issued updated guidance that created a Special Registration framework for telemedicine prescribing of controlled substances.

As of 2026, practitioners who want to prescribe controlled substances via telemedicine without a prior in-person visit must either:

  • Use the DEA’s telemedicine prescribing Special Registration (which requires meeting specific criteria), or
  • Have an established patient relationship that includes at least one in-person evaluation

The DEA’s telemedicine rules are subject to continuing updates. The authoritative source for current requirements is DEA.gov’s Telemedicine page, which is updated as regulations change. Clinics operating telehealth programs should verify current requirements directly with DEA compliance counsel — not from secondary sources.

What This Means for Ketamine Clinic Intake

For clinics that offer ketamine infusions at a physical location but want to conduct the initial evaluation via telehealth, the key question is whether the evaluation itself constitutes a prescribing event that triggers controlled substance prescribing rules. In many ketamine program models, the evaluation does not result in a prescription being sent to a pharmacy — the ketamine is administered directly at the clinic by the clinician. The prescribing event (in a legal sense) occurs when the controlled substance is ordered or administered.

Clinics should consult with healthcare legal counsel about how their specific model is structured. The questions to resolve include:

  • Does the clinician write a prescription, or is ketamine administered under a standing order or administered directly?
  • Is the evaluation visit a standalone billed service, or is it bundled with the infusion series?
  • Is the patient in the same state as the prescribing clinician during a telehealth evaluation? (State-by-state variation here is significant — some states require patient and clinician to be in the same state for telehealth encounters.)

Spravato-Specific Telehealth Considerations

Spravato (esketamine) requires a different analysis. Because Spravato must be administered in a certified REMS setting and the patient must be observed for at least two hours post-dose, the product itself cannot be used purely via telehealth — the drug administration happens in person by definition. However, the prescribing evaluation, follow-up visits, and integration therapy may be conductable via telehealth depending on state law and payer requirements.

For Spravato billing, the evaluation is typically documented using 90791 or an appropriate E/M code. If a follow-up is conducted via telehealth, the place of service code (POS 10 for telehealth off-site, POS 02 for telehealth on-site as applicable) matters for correct claim submission. Medicare and most commercial payers have specific telehealth billing guidelines — verify with your billing team before submitting claims for telehealth evaluation visits.

State Licensing Stays Separate

Federal DEA rules govern Schedule III prescribing in interstate contexts, but state medical licensing rules are a separate compliance layer. A clinician licensed in one state generally cannot conduct an evaluation for a patient in another state, even via telehealth, unless they hold a license in the patient’s state or the state has a telemedicine reciprocity provision.

The Interstate Medical Licensure Compact (IMLC) facilitates multi-state licensure for physicians and is worth understanding if your program serves patients across state lines. The Federation of State Medical Boards maintains information on current Compact member states and eligibility.

Building a Compliant Telehealth Intake in Practice

A compliant telehealth intake for a ketamine program in 2026 generally looks like this:

  1. Initial inquiry and pre-screening — can be handled via any channel (phone, web form, text, telehealth platform)
  2. Psychiatric evaluation (CPT 90791 or appropriate E/M) — conducted by a licensed clinician in a state where both clinician and patient are licensed/located, via telehealth if compliant with DEA and state rules, or in person
  3. Documentation of diagnosis (ICD-10 codes such as F32.9, F33.2, F41.1 as applicable), prior treatment failures, and contraindication screen
  4. Informed consent documenting the off-label nature of IV/IM ketamine
  5. Coordination with infusion site (if the evaluation is remote but infusions happen at a partner clinic or separate facility)

If your program has an infusion partner network, the handoff between remote evaluator and local infusion site needs documented protocols. What information travels with the patient? What does the infusion site need to verify? These are operational and compliance questions worth resolving before you scale.

Keeping Up With Rule Changes

The telehealth prescribing landscape has moved faster in the last four years than in the previous two decades. Regulatory requirements that were accurate when a colleague described them six months ago may have been updated. Build a habit of reviewing DEA guidance and your state medical board’s telehealth policies at least annually — or whenever a significant regulatory action is announced.

For help connecting with compliance resources or to discuss your clinic’s intake design, reach out here.

This content is for educational purposes only and does not constitute medical advice. Consult a licensed clinician about your specific situation.

Drafted by AI and reviewed by our editorial team. Last updated 2026-05-30.